In vitro models for the prediction of in vivo performance of oral dosage forms: Recent progress from partnership through the IMI OrBiTo collaboration

6533b7d3fe1ef96bd1260199

RESEARCH PRODUCT

In vitro models for the prediction of in vivo performance of oral dosage forms: Recent progress from partnership through the IMI OrBiTo collaboration

Cord J. Andreas Christos Reppas Patrick Augustijns Filippos Kesisoglou Mans Minekus Kerstin Julia Schaefer James Butler Mirko Koziolek Philipp Jedamzik Bart Hens Edmund Kostewicz Masoud Jamei James Mann Joachim Brouwers Jennifer B. Dressman Philippe Berben Maria Vertzoni Ronald Schilderink Peter Langguth Werner Weitschies Anette Müllertz Mark Mcallister

subject

Process management UPPER GASTROINTESTINAL-TRACT Administration Oral Pharmaceutical Science 02 engineering and technology WATER DIFFUSIVITY Models Biological 030226 pharmacology & pharmacy Dosage form Biopharmaceutics 03 medical and health sciences 0302 clinical medicine DISINTEGRATION TESTER Humans Pharmacology & Pharmacy WEAK BASES Intersectoral Collaboration Biology TEST DEVICE Dosage Forms ALBENDAZOLE CONCENTRATIONS Science & Technology Human studies business.industry Biopharmaceutics FED STATE CONDITIONS General Medicine 021001 nanoscience & nanotechnology RELEASE TABLETS Gastrointestinal Tract Pharmaceutical Preparations Gastrointestinal Absorption General partnership SOLID DISPERSION New product development Drug release Intersectoral Collaboration 0210 nano-technology business Life Sciences & Biomedicine UPPER SMALL-INTESTINE Oral retinoid Forecasting Biotechnology

description

The availability of in vitro tools that are constructed on the basis of a detailed knowledge of key aspects of gastrointestinal (GI) physiology and their impact on formulation performance and subsequent drug release behaviour is fundamental to the success and efficiency of oral drug product development. Over the last six years, the development and optimization of improved, biorelevant in vitro tools has been a cornerstone of the IMI OrBiTo (Oral Biopharmaceutics Tools) project. By bringing together key industry and academic partners, and by linking tool development and optimization to human studies to understand behaviour at the formulation/GI tract interface, the collaboration has enabled innovation, optimization and implementation of the requisite biorelevant in vitro tools. In this paper, we present an overview of the in vitro tools investigated during the collaboration and offer a perspective on their future use in enhancing the development of new oral drug products. ispartof: EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS vol:136 pages:70-83 ispartof: location:Netherlands status: published

year	journal	country	edition	language
2019-03-01

http://resolver.tudelft.nl/uuid:6d550c74-1751-4915-ba01-df580dc8a211